CV

Syntiant’s Deep Learning Computer Vision Models Deployed on Renesas RZ/V2L Microprocessor

Retrieved on: 
Friday, May 19, 2023
Renesas Electronics, CV, Deep learning, 3D, POS, Intelligence, MPU, Santa Clara Convention Center, CPU, Algorithm, Workload, SDK, Video game

Designed for edge devices and optimized to reduce latency and memory footprint, Syntiant’s hardware-agnostic deep learning models can be used for multiple vision-based applications such as object detection, face recognition, pose estimation, background subtraction and image classification.

Key Points: 
  • Designed for edge devices and optimized to reduce latency and memory footprint, Syntiant’s hardware-agnostic deep learning models can be used for multiple vision-based applications such as object detection, face recognition, pose estimation, background subtraction and image classification.
  • “Our ongoing collaboration with the team at Syntiant now includes integrating their computer vision models into our DRP-AI accelerator core for enhanced AI vision processing,” said Shigeki Kato, vice president of the Enterprise Infrastructure Business Division at Renesas.
  • Models are further optimized to verify performance and reliability​ for high performance across numerous industries, ranging from smart home to retail analytics.
  • Demonstrations of the Syntiant and Renesas RZ/V2L combined solution will occur May 22-24 at the Renesas booth (#403) during the 2023 Embedded Vision Summit at the Santa Clara Convention Center.

Governor Ganjar Pranowo releases Indonesian MSME product for export, valued at IDR7billion

Retrieved on: 
Tuesday, May 16, 2023
2013 Central Java gubernatorial election, IDR, Food, CV, MSME, USD, Government, Republic, Local government, Banyumas Regency, MSME-Champions, Ratna, Publishers' Licensing Services, Ganjar, News, Coffee, Rail freight transport

4 containers of MSME product were released in Purwokerto, Central Java Province, while 3 containers were dispatched from Purbalingga and Pati.

Key Points: 
  • 4 containers of MSME product were released in Purwokerto, Central Java Province, while 3 containers were dispatched from Purbalingga and Pati.
  • The 7 containers of export products included essential oils, organic coconut sugar, processed foods, brooms, organic palm sugar, and handicrafts.
  • Central Java Governor Ganjar Pranowo released seven containers of local MSME product for export to Asia, the Middle East and America.
  • Following the export release, Governor Ganjar Pranowo stated that the support provided by the local government and MSME activists had yielded results.

GumGum's Accredited Contextual Solution, Verity™, Selected As Newest Contextual Vendor by MediaMath

Retrieved on: 
Tuesday, May 16, 2023
Natural language processing, CV, DSP, CTV, MRC, NLP, Media Rating Council, Ecosystem, Mobile phone, Online shopping, Verity

SANTA MONICA, Calif., May 16, 2023 /PRNewswire-PRWeb/ -- GumGum, a contextual-first, global digital advertising platform, today announced that its leading contextual intelligence solution, Verity, will now be available in MediaMath's demand-side platform (DSP) as the first MRC content-level accredited partner.

Key Points: 
  • Advertisers can now take a mindset-first approach across their programmatic campaigns within the MediaMath platform with GumGum Verity.
  • By applying Verity's accredited and advanced technology, advertisers are able to align their ad contextually with relevant content.
  • "We're thrilled to integrate with MediaMath and expand Verity's footprint to another leading DSP," said Hailey Denenberg, interim Head of VerityTM.
  • "We are excited to make the only MRC-accredited contextual provider for content-level analysis, GumGum Verity, available to our clients through the MediaMath platform," said Dawn Valandra, Director of Ecosystem Activation at MediaMath.

Workhorse Group Reports First Quarter 2023 Results

Retrieved on: 
Monday, May 15, 2023
ACT, EV, CV, Q3, U.S. Department of Defense Strategy for Operating in Cyberspace, FedEx Ground, Farmer, FALCON, Green, Grand Forks, North Dakota, W56, Draft horse, Growth, Government, United States Department of the Air Force, Research, Airline, Warehouse, Mobile phone, Beauty salon, Air cargo, Pharmaceutical industry, Aerospace

CINCINNATI, May 15, 2023 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS ) (“Workhorse” or “the Company”), an American technology company with a vision to pioneer the transition to zero emission commercial vehicles, today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • CINCINNATI, May 15, 2023 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS ) (“Workhorse” or “the Company”), an American technology company with a vision to pioneer the transition to zero emission commercial vehicles, today reported financial results for the first quarter ended March 31, 2023.
  • We are making steady progress in expanding our CV dealer network and plan to onboard 8-10 new dealers in 2023.
  • Workhorse will focus on prototype design, test, and build in 2023 and 2024 with production planned to begin 2025.
  • Workhorse is reaffirming its outlook and expects to generate between $75-125 million in revenue in 2023.

EQS-News: Eleving Group S.A.: Eleving Group reports unaudited results for the three months ended on 31 March 2023

Retrieved on: 
Friday, May 12, 2023
Elevance Health, CV, ICR, Carbon footprint, The Elevation Group, Fear, Primero, QOQ, Fintech, Research, Carbon, Eurobond, EBITDA, FX, Growth, ESG, Tourism, Bank, Lithium, Cryptocurrency, EUR

Traditional lease and leaseback products contributed EUR 17.0 mln to the 3M 2023 revenues—up by 12.4% compared to 3M 2022 and up by 2.1% QOQ.

Key Points: 
  • Traditional lease and leaseback products contributed EUR 17.0 mln to the 3M 2023 revenues—up by 12.4% compared to 3M 2022 and up by 2.1% QOQ.
  • Revenues from the consumer loan segment contributed EUR 13.2 mln to the 3M 2023 revenues—down by 26.0% compared to 3M 2022, but stable QOQ.
  • During Q1, Eleving Group continued its course towards a more sustainable future and achieved several milestones in line with its ESG strategic objectives.
  • Consequently, the Group actively evaluates various refinancing opportunities and anticipates disclosing further details in the forthcoming months.

The Esaote Group presents its latest solutions for cardiac imaging at the EACVI Congress in Barcelona (Spain)

Retrieved on: 
Thursday, May 11, 2023
Telehealth, Medicine, Hospital, CV, EBIT, Interventional cardiology, Esaote, Cardiac catheterization, ECG, Medical imaging, Horvitz–Thompson estimator, Cardiology, CCU, Congress, MRI, Health, Magnetic resonance imaging, Acquisition, Cardiac surgery, Artificial intelligence, European Association for Cardio-Thoracic Surgery, ICU, Augment, PMI, Software, Echocardiography

Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.

Key Points: 
  • Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.
  • With the CV-dedicated configuration, Esaote offers best-in-class diagnostic capability and high-level flexibility to cardiologists and mobile service professionals, anytime and anywhere.
  • Leader in the biomedical equipment sector (ultrasound, magnetic resonance imaging, software for managing the diagnostic process).
  • At the end of 2022, the Group had 1,250 employees, with more than half of them in Italy.

The Esaote Group presents its latest solutions for cardiac imaging at the EACVI Congress in Barcelona (Spain)

Retrieved on: 
Thursday, May 11, 2023
Telehealth, Medicine, Hospital, CV, EBIT, Interventional cardiology, Esaote, Cardiac catheterization, ECG, Medical imaging, Horvitz–Thompson estimator, Cardiology, CCU, Congress, MRI, Health, Magnetic resonance imaging, Acquisition, Cardiac surgery, Artificial intelligence, European Association for Cardio-Thoracic Surgery, ICU, Augment, PMI, Software, Echocardiography

Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.

Key Points: 
  • Thanks to Augmented Insight™ solutions, the new MyLab™Omega eXP presented in Barcelona delivers precise quantification while reducing elaboration time and overall examination time.
  • With the CV-dedicated configuration, Esaote offers best-in-class diagnostic capability and high-level flexibility to cardiologists and mobile service professionals, anytime and anywhere.
  • Leader in the biomedical equipment sector (ultrasound, magnetic resonance imaging, software for managing the diagnostic process).
  • At the end of 2022, the Group had 1,250 employees, with more than half of them in Italy.

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, Patent, RSE, Biomedical Advanced Research and Development Authority, CV, Therapy, U.S. Department of Defense Strategy for Operating in Cyberspace, SG, Orion Corporation, Human services, United States Patent and Trademark Office, Ganaxolone, Office of Inspector General, U.S. Department of Health and Human Services, Lennox–Gastaut syndrome, API, Forest Law Enforcement and Governance Program, GAAP, Eugnosta tenacia, Medication, Development, Administration, Patient, Investment, Administration for Strategic Preparedness and Response, Marinus, Epilepsy, MAD, Security (finance), Research, FDA, BARDA, Pharmaceutical industry, Medical device, Fine chemical, Cryptocurrency, TSC, RAISE

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.
  • Entered exclusive distribution and supply agreement with Biologix for ganaxolone in select markets in the Middle East and North Africa.
  • Recognized $3.3 million in net product revenues for the three months ended March 31, 2023.
  • Net product revenue consists of ZTALMY product sales, which was launched in the U.S. in the third quarter of 2022.

FirstBank Focuses on Long-Term Success in the First Quarter of 2023

Retrieved on: 
Wednesday, May 10, 2023
Organic, First Bank, CV, Cryptocurrency, Bank

LAKEWOOD, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- FirstBank , one of the nation’s largest privately held banks with a focus on “banking for good,” released its first-quarter results.

Key Points: 
  • LAKEWOOD, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- FirstBank , one of the nation’s largest privately held banks with a focus on “banking for good,” released its first-quarter results.
  • The bank reported the following quarterly results, representing performance from Dec. 31, 2022 to March 31, 2023:
    Net loan balance increased 1.9 percent to $16.4 billion.
  • During the first quarter, FirstBank also demonstrated a strong commitment to its communities by launching Coachella Valley Giving Day (CV Giving Day), a new 24-hour online giving event that benefits charities in the greater Palm Springs area.
  • This is the third year in a row the bank earned the study’s top rating across six states.

Cumulus Neuroscience Receives FDA 510(k) Clearance for Award-Winning, First-In-Class Neurophysiology Platform for At-Home Use

Retrieved on: 
Thursday, May 4, 2023
Bracco, Gilead Sciences, Drug development, CV, Hope, CCO, CNS, CIC, Neurophysiology, UKCA, Acquisition, Cambridge Innovation Center, Patient, Central nervous system disease, EEG, Adolescence, Alivecor, United Kingdom, Growth, Diagnosis, Ecosystem, FDA, Health, Medivation, Therapy, Medical device, MD, Cumulus cloud, Pfizer

BELFAST, Northern Ireland and CAMBRIDGE, Mass., May 4, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, today announced that its novel, award-winning dry-sensor EEG headset, has been granted 510(k) clearance from the United States Food and Drug Administration (FDA). This represents the second medical device clearance for the headset, which previously received the UK Conformity Assessed (UKCA) mark in the United Kingdom.  

Key Points: 
  • This represents the second medical device clearance for the headset, which previously received the UK Conformity Assessed (UKCA) mark in the United Kingdom.
  • This groundbreaking technology provides a means to initiate clinical studies remotely with data transmitted to the Cumulus Medical Device Hub, allowing healthcare professionals to review EEG recordings in real-time.
  • The company's 510(k) clearance comes on the heels of its appointment of Tina Sampath as Chief Commercial Officer (CCO).
  • Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function.